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Tumor necrosis factor alpha (TNF-alpha) is a protein of a cellular origin belong-
ing to a group of proinflammatory cytokines. A rapid overproduction of TNF-
alpha in a cerebral post-ischemic inflammatory response leads to the stimulation
of adhesive molecules expression with subsequent accumulation of leukocytes
in the ischemic focus, which is preceded by their adhesion and migration. The
TNF-alpha proinflammatory activity results mainly in extending the area of the
brain infarct, which brings about negative clinical implications. Being the final
morphological effect of ischemic stroke, TNF-alpha appears also to contribute
to neuronal necrosis by its involvement in the process of apoptosis as well as in
the death of neurons. The present study describes and discusses mainly the
contribution of TNF-alpha to the formation of ischemic focus in the brain.
key words: tumor necrosis factor alpha (TNF-alpha), proinflammatory
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INTRODUCTION
The key phenomenon contributing to the ischemic
stroke is endothelial transformation altering hemo-
static and immunologic balance towards the pro-
thrombotic and proinflammatory state [46]. The
advance of inflammatory response induced by cere-
bral ischemia and reperfusion leads to leukocyte
migration to the ischemic focus of the brain with
a subsequent leukocyte accumulation. This, in turn,
exacerbates cerebral damage by microvessel occlu-
sion, vasomotor reactivity impairment, oxygen free
radical formation, the release of both cytotoxic en-
zymes and cytokines and chemokines [10]. Recent
research in cerebral ischemia on animal models and
initial studies on humans indicate a significant con-
tribution of cytokines  mainly proinflammatory
ones  to the sequence of inflammatory response
which influences the morphology of cerebral dam-
age [15,26,34].
Cytokines are pleiotropic transmitters of cellular
origin that may affect target cells or cause an auto-
crine effect during intercellular communication. Cy-
tokines are free glycoproteins deprived of immu-
noglobulin properties that act in a non-enzymatic
manner and whose activity is modulated by specific
receptors found on the cell surfaces [1,7]. In the in-
tact brain there is a very small amount of cytokines.
However, those cytokines, which may be synthesized
after damage to cerebral structures and also those
ones that co-operate with other inflammatory agents,
are called proinflammatory cytokines. The above-men-
tioned damage may be due to multietiological fac-
tors such as cerebrovascular diseases, severe cerebro-
cranial traumas, or inflammation [26,34,47,48,60].
The group of proinflammatory cytokines is rep-
resented mainly by tumor necrosis factor alpha (TNF-
alpha) as well as by interleukin-1 beta (IL-1 beta),
interleukin-6 (IL-6), interleukin-8 (IL-8) and by inter-
feron-gamma [44,57,58,64].
In humans the gene for TNF-alpha is situated in a
short branch of the 6th chromosome within the
genes of the main tissue compatibility system. TNF-
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alpha precursor appears on a mother cell surface as
transmembrane protein that is released to the envi-
ronment due to proteinase activity. Biologically ac-
tive TNF-alpha occurs in the form of non-covalently
connected trimmers [20].
So far, the best-known pathophysiological effect
of TNF-alpha activity is cytotoxicity. Such result is
achieved due to TNF-alpha causing haemorrhagic
necrosis of some neoplastic cell lines by apoptosis,
i.e. programmed cell death, possibly by activating
endogenic nucleases [49,50]. TNF-alpha is a cytok-
ine produced mainly by macrophages, monocytes, T
and B lymphocytes, neutrophils, mast cells and ke-
ratinocytes [31].
EARLY TNF-ALPHA EXPRESSION
IN CEREBRAL ISCHEMIA
Recent research carried on animal models and hu-
man material collected at autopsy allowed TNF-al-
pha identification in the ischemic brain in microglial,
astroglial and ependymal cells, in macrophages, and
in neurons both in ischemic focus and penumbric
region [21,37,60,61,67].
Brain ischemia induces a very rapid and dramatic
increase in TNF-alpha synthesis, which is reflected
by the following data: Buttini et al. [8] showed mRNA
TNF-alpha expression in the ischemic region within
0.5 h after onset of a focal ischemia; Feuerstein et
al. [15], Liu et al. [37] and Wang et al. [64] noticed
mRNA TNF-alpha expression with a slight delay, i.e.
within 1 h; moreover, Uno et al. [63] reported TNF-
alpha expression in the brain at 1.5 hrs, and Gong et
al. [21]  3 hrs following focal ischemia.
The period of sustained TNF-alpha expression in the
ischemic brain is 24 hrs by Gong et al. [21] with its max-
imum between 6 and 12 hrs. Buttini et al. [8] and Feuer-
stein et al. [15] reported TNF-alpha mRNA expression
during 12 days following focal cerebral ischemia. Wang
et al. [64] showed increased TNF-alpha mRNA expres-
sion for up to 2 days. However, Liu et al. [37] noticed
TNF-alpha mRNA overexpression significantly longer,
i.e. until the 5th day following focal brain ischemia.
The above studies performed on experimental ani-
mal models prove the occurrence of an increased TNF-
alpha expression as early as in the first few hours of
brain ischemia and determine the duration of this phe-
nomenon for one to a few days. The difference in the
duration observed by different authors may be due to
the pleiotropism of this cytokine the property of which
may also be responsible for various results obtained in
vitro and in vivo as well as in clinical studies.
Both Fassbender et al. [13] and Elneihoum et al.
[12] studying the levels of inflammatory mediators
in serum of patients with ischemic stroke did not
show statistically relevant TNF-alpha concentration
increase between the 4th hour and the 7th day of the
disease. Ferrarese et al. [14] reported a high and sta-
tistically relevantly increased TNF-alpha release from
stimulated blood cells between the 1st2nd and the
90th day after the stroke. They concluded that cere-
bral ischemia induces a prolonged activation of TNF-
alpha production in blood cells of peripheral blood
in humans. Tarkowski et al. [58] studying cytokine
levels in cerebrospinal fluid in patients with stroke
observed increased TNF-alpha concentrations only
in cases of ischemic damage located in white matter
of the brain. Recently we have studied TNF-alpha
levels in cerebrospinal fluid and serum in 30 patients
with stroke within 24 hours after the onset of neu-
rological signs. All studied patients suffered first in-
cidence of the stroke in their lives and brain infarct
affected only white matter. The findings revealed
statistically relevant higher TNF-alpha concentrations
in cerebrospinal fluid and serum in stroke patients
in comparison to the control group. The data of our
study suggest the overproduction of TNF-alpha dur-
ing the first twenty-four hours of stroke [69].
THE INVOLVEMENT OF TNF-ALPHA IN
STROKE PATHOPHYSIOLOGIC
MECHANISM
Contribution of TNF-alpha to ischemic stroke is basi-
cally derived from its proinflammatory activity that
is manifested mainly by induction of upregulation
of the mRNA expression such adhesion molecules as
intercellular adhesion molecule-1 (ICAM-1), endot-
helial-leukocyte adhesion molecule-1 (ELAM-1) and
E-selectin [28,30,32,53,65]. This phenomenon is an
integral part of inflammatory reaction in the post-
ischemic brain as adhesive molecules are responsi-
ble for adhesion and migration of leukocytes to is-
chemic areas [32,65,70]. Infiltration of leukocytes to
ischemic focus is a key morphological element of an
intracerebral inflammatory reaction induced by a
vasogenic process. Such a reaction consists of cellu-
lar presentation (neutrophils followed by monocytes)
that is preceded by mediator activity, where
proinflammatory cytokines, chemokines and adhe-
sive molecules  including integrins  are particu-
larly active [16,19,33].
Another phenomenon fundamental to the cere-
bral ischemic process is damage to the blood-brain
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barrier. TNF-alpha, being a hydrophilic peptide, is
unable to cross the blood-brain barrier without bond-
ing to a membrane receptor. Nevertheless, TNF-al-
pha is able to damage the barrier and its expression
detected in the ischemic brain is suggestive of both
its intrathecal synthesis in the central nervous sys-
tem and pathogenic contribution of haematogenic
TNF-alpha [18,21,51,67]. Previously mentioned
ICAM-1 activation induced by TNF-alpha on the sur-
face of cerebral vessels endothelial cells shows its
significant role in adhesion crucial for crossing the
blood-brain barrier [30]. In the ischemic brain TNF-
alpha has been found both in the astrocyte end-feet
and in ependymal cells which suggests the involve-
ment of this cytokine in the blood-brain barrier dam-
age mechanism [21]. Moreover, TNF-alpha expres-
sion following cerebral ischemia precedes increased
blood-brain barrier permeability [67]. Unos et al.
[63] observation concerning pathophysiological
changes sequence in cerebral ischemia seems to
be of significance here. This author  like many
other researchers [8,60,61]  was observing TNF-
alpha expression in microglial cells. Nevertheless,
he emphasizes the subsequent TNF-alpha presence
in astroglia that implies a two-stage TNF-alpha ex-
pression as well as likelihood of cytokine network
activation in the post-ischemic brain. This activa-
tion is caused by an early TNF-alpha production in
microglia and leads to TNF-alpha synthesis by as-
trocytes.
Research has also shown TNF-alpha expression
of the ischemic brain in macrophages at different
states of activation [8,15,60]. These data correlate
with Hallenbecks et al. [25] reporting an increase
in TNF-alpha synthesis as a result of exogenic li-
popolysaccharide administration known to be a
very strong macrophageal stimulator. Moreover,
Chlamydial and human heat shock protein 60 (HSP
60) induce TNF-alpha production by macrophages
and in this way may promote atherogenesis [35].
Moreover, TNF-alpha increases capillary perme-
ability, activates endothelium and produces a signif-
icant neutrophil adherence and accumulation in cap-
illaries and small blood vessels. Also, early expres-
sion of TNF-alpha in ischemic neurons precedes
leukocyte infiltration to the ischemic area and ap-
pears to facilitate the influx of inflammatory cells
[37]. TNF-alpha causes local microvascular injury in
the form of pericapillary edema and leukocyte ad-
hesion to cerebral capillaries [17]. Last of all, TNF-
alpha exacerbates ischemic brain injury and increas-
es infarct size by several mechanisms, including
thrombus formation, release of endothelin-1 and
nitric oxide  the potent vasoactive agents, promo-
tion of leukocyte adhesion and infiltration, blood-
brain barrier breakdown and tissue swelling
[3,15,17,37,38].
THE RELATIONSHIP BETWEEN
TNF-ALPHA AND CHEMOKINES
IN STROKE
Regarding the pathogenesis of the ischemic brain
damage, the TNF-alpha and chemokines relations are
of special value.
Chemokines are a superfamily of inflammatory
cytokines and they have been shown to chemoattract
and activate different leukocyte populations [68].
TNF-alpha stimulates release of three best-
known beta chemokines  which can play a signif-
icant role in inflammatory processes within the brain
 i.e. macrophage inflammatory protein-1 alpha
(MIP-1 alpha), macrophage inflammatory protein-
1 beta (MIP-1 beta) and monocyte chemotactic pro-
tein-1 (MCP-1) from human foetal microglial cell
and astrocyte cultures [45]. Macrophage inflamma-
tory protein-1 (MIP-1) is implicated in the inflam-
matory reaction of the brain in response to ischemia
[22]. MIP-1 alpha mRNA was induced by middle
cerebral artery occlusion with the peak of expres-
sion at 46 hrs after the onset of occlusion, and the
signals of MIP-1 alpha mRNA were observed in the
ischemic core and in the penumbra in microglia/
macrophages of the rat brain after focal cerebral
ischemia [56]. Here, it may be worth adding that
anti-tumor necrosis factor alpha antibody prevent-
ed MCP-1 release [11].
Astrocytes constitute a part of the blood-brain
barrier. Chemokine expression by astrocytes may con-
tribute to leukocyte infiltration within the central ner-
vous system during inflammation. TNF-alpha induc-
es mRNAs expression of such beta chemokines as
MCP-1 and MIP-1 beta in rat astrocytes. Transform-
ing growth factor-beta 1 (TGF-beta 1) and interleu-
kin-10 (IL-10) down-regulate MCP-1 mRNA expres-
sion induced by TNF-alpha. On the other hand IL-10,
but not TGF-beta 1, inhibits MIP-1 beta mRNA ex-
pression induced by TNF-alpha. The results of this in
vitro study suggest that TNF-alpha as a proinflam-
matory cytokine can induce these astrocyte-derived
beta-family chemokine mRNAs expressions, where-
as regulatory cytokines, such as TGF-beta 1 and IL-
10 down-regulate them [23].
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THE ROLE OF THE LOCALIZED
SHWARTZMAN PHENOMENON IN
THE DEVELOPMENT OF STROKE
IN RELATION TO TNF-ALPHA
Hallenbeck [27] and Siren et al. [54,55] have been
interested in the potential relationship between the
localized Shwartzman phenomenon and acute
stroke. The essence of this phenomenon is that ves-
sel segments exposed to TNF-alpha and interleukin-
1 (IL-1) [40] become activated and prepared in such
a way that the occurrence of an additional provoca-
tive step causes local thrombosis. The provocative
step involves activation of the coagulation system
or inflammation with activation of a complement
[41]. Most likely a mechanism similar to the Shwartz-
man phenomenon operates in the genesis of stroke;
a vessel segment periodically exposed to effective
levels of the cytokines TNF-alpha and IL-1 would be
brought into a state in which its endothelium would
be activated [6,43], and the vessel segment could
be considered prepared and ready to be triggered
for a period of hours. This way, during this critical
interval, the coagulation or complement system
should become activated (the provocative stimulus)
and the prepared vessel segment could undergo
thrombosis.
Hallenbeck et al. [24] showed that various stroke
risk factors effectively prepared the brainstem vas-
culature of rats for a localized Shwartzman reaction.
Rats with hypertension, hypertension and genetic
stroke predisposition, of advanced age, and strep-
tozotocin-induced diabetes reacted with a signifi-
cantly higher incidence of strokes than rats devoid
of such stroke risk factors. In further studies Hallen-
beck [27] demonstrated that the stroke risk factor,
hypertension, is associated with preparation of brain
vessels to thrombosis, increased perivascular mono-
cyte and macrophage accumulation, increased stim-
ulated TNF-alpha release from blood vessels and brain
cells, and increased response of cerebral microves-
sel endothelial cells to TNF-alpha and IL-1.
Studies reported that risk factors for stroke pre-
pare brainstem tissue for a localized Shwartzman
reaction, including the development of ischemia and
the production of TNF-alpha after a provocative dose
of lipopolysaccharide. Moreover, these studies indi-
cated that rats with stroke risk factors, such as hy-
pertension and advanced age, respond to li-
popolysaccharide with a more exuberant production
of TNF-alpha and platelet activating factor than
young and normotensive rats. These findings are
consistent with the hypothesis that perivascular cells
are capable of exaggerated signalling of endotheli-
um through cytokines such as TNF-alpha in animals
with stroke risk factors. The effect of such signaling
might be to prepare the endothelial local vascular
segment for thrombosis in accordance with the lo-
cal Shwartzman reaction paradigm [54,55].
It might be worth noticing that TNF-alpha, plate-
let activating factor and IL-1 together participate in
leukocyte accumulation and subsequent activation.
This mechanism contributes to the extension of the
infarct area and destruction of the microvasculature
sustained by the central nervous system after cere-
bral reperfusion [33]. Moreover, it must be empha-
sized that TNF-alpha activity causes the fall in nitric
oxide synthase that may lead to the spread of is-
chemic focus volume by the reduction of vasodilat-
ing mechanism [62]. On the other hand, though, TNF-
alpha induces vasodilation [52]. These antagonistic
vasogenic effects performed by TNF-alpha may be
connected with interactions between ischemia-in-
duced sequence of inflammatory changes together
with cerebral reperfusion and the progress of patho-
morphological lesions in an ischemic area of the brain.
INHIBITION OF TNF-ALPHA REDUCES
BRAIN INFARCT VOLUME
The TNF-alpha synthesis or activity inhibitors may
decrease infiltration of leukocytes to ischemic area
of the brain thus reducing the infarct volume [15].
Inhibition of TNF-alpha involves blocking of TNF-al-
pha with specific antibodies or soluble TNF receptor
I (sTNF-RI) and other neuroprotective agents like dex-
anabinol, MK 801, dexamethasone and CNI-1493.
Monoclonal neutralizing anti-TNF-alpha antibody
administered intracerebroventricularly (or into the
brain cortex [39]) in the experimental animals with
middle cerebral artery occlusion significantly decreas-
es focal ischemic brain injury [3,66].
sTNF-RI in higher concentrations is a natural in-
hibitor of endogenous TNF-alpha. Thus, adminis-
tered intracerebroventricularly also reduced brain
infarction [3]. sTNF-RI linked to polyethylene glycol
(TNFbp) produced a significant reduction in the
cortical infarct volume [42]. Plasma soluble tumor
necrosis factor receptor protein-1 (sTNFR-1) levels
are increased after acute cerebral ischemia and re-
lated to both intraplatelet cGMP and cAMP (which
mediates the effects of vasodilatory and platelet an-
tiaggregatory factors such as nitric oxide and pros-
tacyclin, respectively) levels, indicating chronic in-
flammatory activity connected with late protective
endothelial activation [2].
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Dexanabinol (HU-211), a synthetic cannabinoid,
is a noncompetitive N-methyl-D-aspartate antago-
nist with antioxidating and anti-TNF-alpha proper-
ties. Dexanabinol significantly decreases brain inf-
arct volume and significantly lowers TNF-alpha lev-
els [36].
Both MK 801, a noncompetitive NMDA receptor
antagonist and dexamethasone reduced TNF produc-
tion and decreased brain infarct volume [5].
CNI-1493, tetravalent guanylhydrazone com-
pound effectively inhibited endogenous brain TNF
synthesis and significantly reduced brain infarct vol-
ume. It seems very important that specific antibod-
ies anti-TNF and CNI-1493 were each cerebroprotec-
tive when given within a clinically relevant time for
up to 2 hrs after the onset of ischemia. These find-
ings suggest that inhibiting TNF with CNI-1493 (just
by systemic administration) may be beneficial in the
future treatment of stroke [39].
Moreover, the finding that brain ischemia trig-
gers inflammation in the brain with its rapid onset
and progress over many hours after stroke and its
contribution to the increase of infarct size brings
about the search of selective inhibitors for specific
inflammatory mediators. Inhibition of the mitogen-
activated protein kinase (MAPK) cascade via cytok-
ine suppressive anti-inflammatory drugs blocks the
production of TNF-alpha [4].
Catania and Lipton [9] mention that alpha-mel-
anocyte stimulating hormone (alpha-MSH) is a neu-
ropeptide which exerts an anti-inflammatory activ-
ity via direct actions on peripheral host cells, de-
scending neurogenic anti-inflammatory pathways
stemming from central nervous system melanocor-
tin receptors, and local actions on receptors that
control inflammation within the brain. Respecting
the latter influence there are reports that alpha-
MSH inhibits TNF-alpha. alpha-MSH administered
systemically modulates disturbances of auditory
evoked potentials induced by ischemia/reperfusion
of the brain in the posterior circulation. Such influ-
ences of the peptide may occur through inhibition
of inflammatory factors produced by glia, namely
alpha-MSH modulate TNF-alpha produced both by
activated murine microglia and human astrocytes.
Because glia can secrete alpha-MSH and express
melanocortin receptors, they may, like peripheral
macrophages, contain autocrine regulatory circuits
based on the peptide and thus alpha-MSH modu-
lated inflammation in the brain by acting on local
melanocortin receptors.
TNF-ALPHA CONTRIBUTES TO
APOPTOSIS IN STROKE
Programmed cell death, or apoptosis, may contrib-
ute to a neuronal death that accompanies stroke [59].
Recently, Herr et al. [29] have indirectly shown that
in cerebral ischemia TNF-alpha may contribute to
cytotoxicity through apoptosis, and to cell necrosis.
Well, middle cerebral artery occlusion in rats leads
to increased synthesis of ceramide in ischemic brain.
Ceramide is a key mediator of apoptosis that is
also involved in a stroke-induced death. Synthetic
C2-ceramide causes increased expression of TNF-al-
pha and induces both necrosis and apoptosis in the
ischemic brain.
Control of factors regulating apoptosis may lead
to a decreased brain damage in stroke.
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